221 related articles for article (PubMed ID: 33400743)
1. Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors.
Bielecki PA; Lorkowski ME; Becicka WM; Atukorale PU; Moon TJ; Zhang Y; Wiese M; Covarrubias G; Ravichandran S; Karathanasis E
Nanoscale Horiz; 2021 Feb; 6(2):156-167. PubMed ID: 33400743
[TBL] [Abstract][Full Text] [Related]
2. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer.
Covarrubias G; Moon TJ; Loutrianakis G; Sims HM; Umapathy MP; Lorkowski ME; Bielecki PA; Wiese ML; Atukorale PU; Karathanasis E
J Mater Chem B; 2022 Jan; 10(2):224-235. PubMed ID: 34846443
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors.
Lorkowski ME; Atukorale PU; Bielecki PA; Tong KH; Covarrubias G; Zhang Y; Loutrianakis G; Moon TJ; Santulli AR; Becicka WM; Karathanasis E
J Control Release; 2021 Feb; 330():1095-1105. PubMed ID: 33188827
[TBL] [Abstract][Full Text] [Related]
5. The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment.
Becicka WM; Bielecki PA; Lorkowski ME; Moon TJ; Zhang Y; Atukorale PU; Covarrubias G; Karathanasis E
Nanoscale Adv; 2021 Aug; 3(17):4961-4972. PubMed ID: 34485818
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.
Atukorale PU; Raghunathan SP; Raguveer V; Moon TJ; Zheng C; Bielecki PA; Wiese ML; Goldberg AL; Covarrubias G; Hoimes CJ; Karathanasis E
Cancer Res; 2019 Oct; 79(20):5394-5406. PubMed ID: 31431457
[TBL] [Abstract][Full Text] [Related]
7. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
[TBL] [Abstract][Full Text] [Related]
8. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity.
McAndrews KM; Che SPY; LeBleu VS; Kalluri R
J Biol Chem; 2021; 296():100523. PubMed ID: 33711340
[TBL] [Abstract][Full Text] [Related]
9. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
Nguyen TL; Choi Y; Kim J
Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
[TBL] [Abstract][Full Text] [Related]
10. Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity.
An M; Yu C; Xi J; Reyes J; Mao G; Wei WZ; Liu H
Nanoscale; 2018 May; 10(19):9311-9319. PubMed ID: 29737353
[TBL] [Abstract][Full Text] [Related]
11. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
12. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
[TBL] [Abstract][Full Text] [Related]
13. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
14. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
16. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
17. Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.
Castro F; Pinto ML; Silva AM; Pereira CL; Teixeira GQ; Gomez-Lazaro M; Santos SG; Barbosa MA; Gonçalves RM; Oliveira MJ
Acta Biomater; 2017 Nov; 63():96-109. PubMed ID: 28919508
[TBL] [Abstract][Full Text] [Related]
18. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
[TBL] [Abstract][Full Text] [Related]
19. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
Liu Y; Crowe WN; Wang L; Lu Y; Petty WJ; Habib AA; Zhao D
Nat Commun; 2019 Nov; 10(1):5108. PubMed ID: 31704921
[TBL] [Abstract][Full Text] [Related]
20. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment.
Lam KC; Araya RE; Huang A; Chen Q; Di Modica M; Rodrigues RR; Lopès A; Johnson SB; Schwarz B; Bohrnsen E; Cogdill AP; Bosio CM; Wargo JA; Lee MP; Goldszmid RS
Cell; 2021 Oct; 184(21):5338-5356.e21. PubMed ID: 34624222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
